Related Experiment Video
Updated: Jul 18, 2025

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis
Published on: June 14, 2019
Unveiling the multitargeted potency of Sodium Danshensu against cervical cancer: a multitargeted docking-based,
Saad Alghamdi1, Hanadi M Baeissa2, Mohammad Azhar Kamal3
1Laboratory Medicine Department, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia.
Abstract:
Cervical Cancer (CC) is one of the most common types of cancer in women worldwide, with a significant number of deaths reported yearly. Despite the various treatment options available, the high mortality rate associated with CC highlights the need to develop new and effective therapeutic agents. In this study, we have screened the complete prepared FDA library against the Mitotic kinesin-like protein 1, Cyclin B1, DNA polymerase, and MCM10-ID using three glide-based molecular docking algorithms: HTVS, SP and XP to produce a robust calculation. All four proteins are crucial proteins that actively participate in CC development, and inhibiting them together can be a game-changer step for multitargeted drug designing. Our multitargeted screening identified Sodium (Na) Danshensu, a natural FDA-approved phenolic compound of caffeic acid derivatives isolated from Salvia miltiorrhiza. The docking score ranges from -5.892 to -13.103 Kcal/mol, and the screening study was evaluated with the pharmacokinetics and interaction fingerprinting to identify the pattern of interactions that revealed that the compound has bound to the best site it can be fitted to where maximum bonds were created to make the complex stable. The molecular dynamics simulations for 100 ns were then extended to validate the stability of the protein-ligand complexes. The results provide insight into the repurposing, and Na-danshensu exhibited strong binding affinity and stable complex formation with the target proteins, indicating its potential as a multitargeted drug against CC.Communicated by Ramaswamy H. Sarma.
Insights
This study identified Sodium Danshensu as a potential multitargeted drug for cervical cancer (CC). This natural compound effectively targets key proteins involved in CC development, showing promise for new therapeutic strategies.
Area of Science:
- Biochemistry
- Computational Chemistry
- Oncology
Background:
- Cervical cancer (CC) remains a leading cause of cancer deaths in women globally.
- Existing treatments for CC have limitations, necessitating the development of novel therapeutic agents.
Purpose of the Study:
- To identify potential multitargeted drug candidates for cervical cancer (CC) by screening FDA-approved compounds.
- To evaluate the efficacy of identified compounds against key proteins involved in CC progression.
Main Methods:
- Utilized molecular docking algorithms (HTVS, SP, XP) to screen an FDA library against Mitotic kinesin-like protein 1, Cyclin B1, DNA polymerase, and MCM10-ID.
- Assessed binding affinity, pharmacokinetics, and interaction fingerprinting of potential drug candidates.
- Performed 100 ns molecular dynamics simulations to validate the stability of protein-ligand complexes.
Main Results:
- Sodium (Na) Danshensu, a natural phenolic compound, was identified as a promising candidate.
- Na-danshensu demonstrated strong binding affinity (docking scores -5.892 to -13.103 Kcal/mol) and stable complex formation with target proteins.
- Molecular dynamics simulations confirmed the stability of the Na-danshensu-protein complexes.
Conclusions:
- Na-danshensu shows significant potential for drug repurposing as a multitargeted therapeutic agent against cervical cancer (CC).
- The compound's ability to form stable complexes with multiple CC-related proteins supports its candidacy for novel CC drug development.
More Related Videos
09:03Establishment of Hepatocarcinoma in BALB/c-nu Mice and Investigation of the Therapeutic Effect of the Sanleng Jiashen Formula
Published on: January 26, 2024
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016